Introduction:
The efficacy of recombinant adjuvanted vaccine (RZV) against Herpes Zoster (HZ) is universally recognized and is the only safe vaccine in immunocompromised persons and in higher-risk individuals. Higher-risk patients with primary or acquired immunodeficiencies are characterized by an increased risk of disseminated infection after HZ infection or after reactivation of HZ virus, due to their clinically fragile condition. To date, the rate of vaccination with RZV through non-hospital health services in this population does not reach optimal standards, either because of difficulties in accessing care or because of vaccine hesitancy (VH). According to the latest international guidelines, interventions to support community medicine are needed to increase vaccination coverage and to counteract VH.
Methods
The Fondazione Policlinico Universitario Agostino Gemelli IRCCS Hospital in Rome performed an organizational management model including the hospital and non-hospital health services (ASL Roma 1) dedicated to vaccine counseling and contrasting VH in frail patients with an indication for RZV vaccination. Multiple linear regression was used to analyze the impact of results.
Results
From July 2022 to July 2023, 178 patients underwent vaccine counseling and received two doses of RZV vaccine, of which, 90 responded to the recall to evaluate side effects, breakthrough HZ Infections and answered to the VAX Scale questionnaire. 34.27% were affected by HIV infection, 23% by HZ relapses or severe forms, and 21.35% by rheumatologic diseases. Total VH score tot 2.291. A statistically significant correlation was demonstrated between age/rheumatology patients/female sex and overall vaccine hesitancy. 80% and 74.44% of patients had no short-term side effects after the first and second doses, respectively. 3.33% had breakthrough HZ Infections. No patients had minor or major long-term (1 year) side effects. Comparison of responses to VAX scale in the first and recall phase, showed positive changes about VH, with differences ranging from 2.9 to 3.0 points.
Conclusions
This study demonstrates that a multidisciplinary approach to vaccine counseling can significantly reduce vaccine hesitancy and improve adherence among frail, high-risk patients.
Trial registration:
ClinicalTrials.gov ID: NCT06334861; date of registration: 2023-03-13